Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache.

ABSTRACT: BACKGROUND:Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) induces headache in healthy volunteers but the precise mechanisms by which PACAP38 leads to headache are unclear. We investigated the headache preventive effect of sumatriptan and ketorolac on PACAP38-induced headache in healthy volunteers. In addition, we explored contribution of vascular mechanisms to PACAP38-induced headache using high resolution magnetic resonance angiography. METHODS:Thirty-four healthy volunteers were divided in two groups (A and B) and received infusion of PACAP38 (10 picomol/kg/min) over 20?min. Group A was pretreated with intravenous sumatriptan (4?mg) or ketorolac (30?mg) 20?min before infusion of PACAP38. Group B received infusion of sumatriptan or ketorolac as post-treatment 90?min after infusion of PACAP38. In both experiments, we used a randomized, double-blind, cross-over design. We recorded headache characteristics and circumference of extra-intracerebral arteries. RESULTS:We found no difference in AUC (0-6 h) of PACAP38-induced headache in group A, pretreated with sumatriptan or ketorolac (p?=?0.297). There was no difference between sumatriptan and ketorolac in PACAP38-induced circumference change (AUCBaseline-110 min) of MMA (p?=?0.227), STA (p?=?0.795) and MCA (p?=?0.356). In group B, post-treatment with ketorolac reduced PACAP38-headache compared to sumatriptan (p?

SUBMITTER: Ghanizada H 

PROVIDER: S-EPMC7038568 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature